公开(公告)号：US20170197939A1

公开(公告)日：2017-07-13

申请号：US15300440

申请日：2015-04-01

Applicant: PFIZER INC.

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: C07D401/14 ,  A61K31/4439 ,  C07D401/12

CPC classification number: C07D401/14 ,  A61K31/4439 ,  C07D401/12

Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

公开(公告)号：US09328096B2

公开(公告)日：2016-05-03

申请号：US14705272

申请日：2015-05-06

Applicant: PFIZER INC

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: A61P35/00 ,  C07D413/14 ,  A61P29/00 ,  C07D405/14 ,  A61K31/4439 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，特别是作为TrkA拮抗剂。

公开(公告)号：US20220363673A1

公开(公告)日：2022-11-17

申请号：US17619912

申请日：2020-06-24

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Christopher Ryan Butler ,  Kevin James Filipski ,  Bethany Lyn Kormos ,  Luis Angel Martinez-Alsina ,  Russell Alan Miller ,  Kiyoyuki Omoto ,  Brian Raymer ,  Matthew Richard Reese ,  Rachel Jane Roth Flach ,  Yuan Zhang

IPC: C07D409/04 ,  A61K45/06 ,  A61K31/41 ,  A61P3/10 ,  A61P9/04

Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

公开(公告)号：US20160221989A1

公开(公告)日：2016-08-04

申请号：US14817416

申请日：2015-08-04

Applicant: Pfizer Inc.

Inventor： Sharanjeet Kaur Bagal ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Michelle Bich Tran-Dubé

IPC: C07D401/12 ,  A61K31/4439

CPC classification number: C07D401/12 ,  A61K31/4439

Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.

Abstract translation: 本发明涉及本文所述的式I化合物及其药学上可接受的盐，以及它们在医药中的用途，特别是作为Trk拮抗剂。